X0508 4 2026-01-02 0001133416 GALECTIN THERAPEUTICS INC GALT 0001725595 LEWIS JOEL C/O GALECTIN THERAPEUTICS INC. 4960 PEACHTREE INDUSTRIAL BLVD., STE 240 NORCROSS GA 30071 true true false false President and CEO true Common Stock 2026-01-02 4 M false 84000 0 A 916592 D Common Stock 2026-01-02 4 S false 18571 4.1968 D 898021 D Common Stock 2026-01-05 4 S false 27731 3.9069 D 870290 D Common Stock 2026-01-06 4 S false 37698 3.5772 D 832592 D Common Stock 2000 I as USTA custodian for a minor child Restricted Stock Unit 0 2026-01-02 4 M false 84000 0 D 2026-01-01 Common Stock 84000 0 D The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units. These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose. The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026. The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The shares were sold in multiple transactions at prices ranging from $3.36 to $3.79. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Jack W. Callicutt, by power of attorney 2026-01-06